Haupt A - Search Results

1

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.

Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL. Pirro V, et al. Among authors: haupt a. J Clin Endocrinol Metab. 2022 Jan 18;107(2):363-378. doi: 10.1210/clinem/dgab722. J Clin Endocrinol Metab. 2022. PMID: 34608929 Clinical Trial.

2

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.

Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM, Higdon AN, Bastyr EJ 3rd, Haupt A, Hartman ML. Cusi K, et al. Among authors: haupt a. Diabetes Obes Metab. 2016 Oct;18 Suppl 2:50-58. doi: 10.1111/dom.12751. Diabetes Obes Metab. 2016. PMID: 27723227

3

Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.

Jacober SJ, Prince MJ, Beals JM, Hartman ML, Qu Y, Linnebjerg H, Garhyan P, Haupt A. Jacober SJ, et al. Among authors: haupt a. Diabetes Obes Metab. 2016 Oct;18 Suppl 2:3-16. doi: 10.1111/dom.12744. Diabetes Obes Metab. 2016. PMID: 27723228 Review.

4

Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.

Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Cusi K, et al. Among authors: haupt a. Diabetes Obes Metab. 2017 Nov;19(11):1630-1634. doi: 10.1111/dom.12973. Epub 2017 Jun 22. Diabetes Obes Metab. 2017. PMID: 28417532

5

The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.

Pillai S, Duvvuru S, Bhatnagar P, Foster W, Farmen M, Shankar S, Harris C, Bastyr E 3rd, Hoogwerf B, Haupt A. Pillai S, et al. Among authors: haupt a. Pharmacogenomics J. 2018 May 22;18(3):487-493. doi: 10.1038/tpj.2017.45. Epub 2017 Nov 21. Pharmacogenomics J. 2018. PMID: 29160303 Clinical Trial.

6

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.

Mathieu C, Del Prato S, Botros FT, Thieu VT, Pavo I, Jia N, Haupt A, Karanikas CA, García-Pérez LE. Mathieu C, et al. Among authors: haupt a. Diabetes Obes Metab. 2018 Aug;20(8):2023-2028. doi: 10.1111/dom.13313. Epub 2018 May 2. Diabetes Obes Metab. 2018. PMID: 29603872 Free PMC article. Clinical Trial.

7

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.

Cusi K, Sattar N, García-Pérez LE, Pavo I, Yu M, Robertson KE, Karanikas CA, Haupt A. Cusi K, et al. Among authors: haupt a. Diabet Med. 2018 Oct;35(10):1434-1439. doi: 10.1111/dme.13697. Epub 2018 Jun 22. Diabet Med. 2018. PMID: 29869810

8

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Frias JP, et al. Among authors: haupt a. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293770 Clinical Trial.

9

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. Coskun T, et al. Among authors: haupt a. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. Mol Metab. 2018. PMID: 30473097 Free PMC article. Clinical Trial.

10

Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE. Giorgino F, et al. Among authors: haupt a. Diabetes Obes Metab. 2019 Nov;21(11):2570-2575. doi: 10.1111/dom.13844. Epub 2019 Aug 16. Diabetes Obes Metab. 2019. PMID: 31364266 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page